Clinical Trial Detail

NCT ID NCT02321540
Title A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

lung non-small cell carcinoma

Therapies

Ibrutinib

Age Groups: adult

No variant requirements are available.